Key Drivers
- High liquidity
- No revenue
- Persistent burn
AIAI Summary
SLS is now a binary, time-compressed speculative bet: recent warrant-driven cash extends runway enough to reach two decisive 2026 readouts (REGAL final and SLS009 topline), so investors should treat valuation (~$934M) as event-driven—monitor cash burn vs. readout timing, SLS009's small N/statistical power, and whether price holds above $4.15 into the catalysts because clear positive signals could trigger rapid re-rating and partnering while ambiguous/negative outcomes will likely cause steep value compression and renewed dilution.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High liquidity
- •No revenue
- •Persistent burn
SLS is well-capitalized with very low debt but is a pre-revenue, cash-burning company with substantial operating losses and negative free cash flow that currently relies on external financing.
Price Behavior
Key Price Behavior Insights:
- •15% month gain
- •steep short-term pullback
- •elevated volatility
Over the last month SLS rallied ~15% from $4.15 to $4.76 with a momentum-driven peak at $5.96 but recent steep pullback and short-term downtrend warn caution unless $4.15 support holds.
~43% high-to-low swing in the period with a rapid rally to $5.96 then sharp drop to $4.76
Sentiment & News
Key News Insights:
- •Clinical milestones
- •Heavy options flow
- •Sharp price volatility
SELLAS is seeing converging clinical catalysts (REGAL Phase 3 timing, new SLS009 enrollment and AACR data) and heavy investor/speculative activity that have driven extreme stock volatility and large options volume.
Near-term trial readouts and data presentations are likely to continue driving outsized share-price swings and heightened trading activity
Similar Companies in Healthcare
Other companies in the same sector with AI ratings